FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091485135> ?p ?o ?g. }

• W2091485135 endingPage "74" @default.
• W2091485135 startingPage "66" @default.
• W2091485135 abstract "Obesity is an increasingly observed pathologic entity in the industrialized world and causally linked to the development of hypertension. Consequently, not only the prevalence of obesity but also the prevalence of obesity hypertension is increasing worldwide. In the context of antihypertensive treatment, data from clinical trials indicate that all first-line antihypertensive drugs possess a similar efficacy in reducing systemic blood pressure and hypertension-related end-organ damage in obese hypertensive subjects. Nevertheless, some antihypertensive agents, such as β-blockers or thiazide diuretics, may have unwanted side effects on the metabolic and hemodynamic abnormalities that occur in both obesity and hypertension. However, current guidelines still do not include recommendations for state-of-the-art treatment of obese patients with hypertension. Hence, the aim of this article is to provide recommendations for the appropriate use of antihypertensive agents in obese patients mostly based on personal expertise and pathophysiologic assumptions. For instance, thiazide diuretics and β-blockers are reported to reduce insulin sensitivity and (at least transiently) increase triglyceride and low-density lipoprotein cholesterol levels, whereas calcium channel blockers are metabolically neutral and angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and renin inhibition may increase insulin sensitivity. The renin-angiotensin-aldosterone system in the adipose tissue has been implicated in the development of arterial hypertension and sodium retention plays a central role in the development of obesity-related hypertension. Therefore, treatment with a blocker of the renin-angiotensin-aldosterone-system and a thiazide diuretic should be considered as first-line antihypertensive drug therapy in obesity hypertension. Obesity is an increasingly observed pathologic entity in the industrialized world and causally linked to the development of hypertension. Consequently, not only the prevalence of obesity but also the prevalence of obesity hypertension is increasing worldwide. In the context of antihypertensive treatment, data from clinical trials indicate that all first-line antihypertensive drugs possess a similar efficacy in reducing systemic blood pressure and hypertension-related end-organ damage in obese hypertensive subjects. Nevertheless, some antihypertensive agents, such as β-blockers or thiazide diuretics, may have unwanted side effects on the metabolic and hemodynamic abnormalities that occur in both obesity and hypertension. However, current guidelines still do not include recommendations for state-of-the-art treatment of obese patients with hypertension. Hence, the aim of this article is to provide recommendations for the appropriate use of antihypertensive agents in obese patients mostly based on personal expertise and pathophysiologic assumptions. For instance, thiazide diuretics and β-blockers are reported to reduce insulin sensitivity and (at least transiently) increase triglyceride and low-density lipoprotein cholesterol levels, whereas calcium channel blockers are metabolically neutral and angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and renin inhibition may increase insulin sensitivity. The renin-angiotensin-aldosterone system in the adipose tissue has been implicated in the development of arterial hypertension and sodium retention plays a central role in the development of obesity-related hypertension. Therefore, treatment with a blocker of the renin-angiotensin-aldosterone-system and a thiazide diuretic should be considered as first-line antihypertensive drug therapy in obesity hypertension." @default.
• W2091485135 created "2016-06-24" @default.
• W2091485135 creator A5051734171 @default.
• W2091485135 creator A5053656881 @default.
• W2091485135 creator A5091511539 @default.
• W2091485135 date "2013-01-01" @default.
• W2091485135 modified "2023-10-16" @default.
• W2091485135 title "Treatment of Arterial Hypertension in Obese Patients" @default.
• W2091485135 cites W1561463821 @default.
• W2091485135 cites W1603805075 @default.
• W2091485135 cites W176668205 @default.
• W2091485135 cites W180946569 @default.
• W2091485135 cites W1971175039 @default.
• W2091485135 cites W1974587800 @default.
• W2091485135 cites W1976031443 @default.
• W2091485135 cites W1977858848 @default.
• W2091485135 cites W1980038148 @default.
• W2091485135 cites W1986625965 @default.
• W2091485135 cites W1992600497 @default.
• W2091485135 cites W1995641756 @default.
• W2091485135 cites W1996424532 @default.
• W2091485135 cites W2007653610 @default.
• W2091485135 cites W2020498330 @default.
• W2091485135 cites W2028046440 @default.
• W2091485135 cites W2032283010 @default.
• W2091485135 cites W2036318692 @default.
• W2091485135 cites W2042663838 @default.
• W2091485135 cites W2045285495 @default.
• W2091485135 cites W2047923125 @default.
• W2091485135 cites W2052520634 @default.
• W2091485135 cites W2056976690 @default.
• W2091485135 cites W2057212652 @default.
• W2091485135 cites W2059665052 @default.
• W2091485135 cites W2064760617 @default.
• W2091485135 cites W2072206476 @default.
• W2091485135 cites W2072828651 @default.
• W2091485135 cites W2074618092 @default.
• W2091485135 cites W2080953758 @default.
• W2091485135 cites W2088112872 @default.
• W2091485135 cites W2090475555 @default.
• W2091485135 cites W2102036895 @default.
• W2091485135 cites W2103256591 @default.
• W2091485135 cites W2113551865 @default.
• W2091485135 cites W2114333967 @default.
• W2091485135 cites W2115479774 @default.
• W2091485135 cites W2117260106 @default.
• W2091485135 cites W2118458077 @default.
• W2091485135 cites W2124086310 @default.
• W2091485135 cites W2124395997 @default.
• W2091485135 cites W2125280221 @default.
• W2091485135 cites W2129991662 @default.
• W2091485135 cites W2133217116 @default.
• W2091485135 cites W2135100154 @default.
• W2091485135 cites W2139400805 @default.
• W2091485135 cites W2146728882 @default.
• W2091485135 cites W2148897749 @default.
• W2091485135 cites W2149207625 @default.
• W2091485135 cites W2152798629 @default.
• W2091485135 cites W2156121263 @default.
• W2091485135 cites W2156734296 @default.
• W2091485135 cites W2159934415 @default.
• W2091485135 cites W2160117042 @default.
• W2091485135 cites W2163833854 @default.
• W2091485135 cites W2324907773 @default.
• W2091485135 cites W2477567742 @default.
• W2091485135 cites W2562329777 @default.
• W2091485135 cites W2573917889 @default.
• W2091485135 cites W4235435263 @default.
• W2091485135 doi "https://doi.org/10.1016/j.semnephrol.2012.12.009" @default.
• W2091485135 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23374895" @default.
• W2091485135 hasPublicationYear "2013" @default.
• W2091485135 type Work @default.
• W2091485135 sameAs 2091485135 @default.
• W2091485135 citedByCount "13" @default.
• W2091485135 countsByYear W20914851352013 @default.
• W2091485135 countsByYear W20914851352014 @default.
• W2091485135 countsByYear W20914851352016 @default.
• W2091485135 countsByYear W20914851352020 @default.
• W2091485135 countsByYear W20914851352021 @default.
• W2091485135 countsByYear W20914851352022 @default.
• W2091485135 crossrefType "journal-article" @default.
• W2091485135 hasAuthorship W2091485135A5051734171 @default.
• W2091485135 hasAuthorship W2091485135A5053656881 @default.
• W2091485135 hasAuthorship W2091485135A5091511539 @default.
• W2091485135 hasConcept C126322002 @default.
• W2091485135 hasConcept C134018914 @default.
• W2091485135 hasConcept C151730666 @default.
• W2091485135 hasConcept C164705383 @default.
• W2091485135 hasConcept C2778525890 @default.
• W2091485135 hasConcept C2779343474 @default.
• W2091485135 hasConcept C2779918671 @default.
• W2091485135 hasConcept C2780192228 @default.
• W2091485135 hasConcept C2780437262 @default.
• W2091485135 hasConcept C511355011 @default.
• W2091485135 hasConcept C57190642 @default.
• W2091485135 hasConcept C71924100 @default.
• W2091485135 hasConcept C84393581 @default.
• W2091485135 hasConcept C86803240 @default.

• next